Arena, Like Rivals, Greets Mixed Phase III Obesity Results With Brave Face
Arena's release this week of surprisingly disappointing results for its obesity drug lorcaserin raises more questions about what "efficacy" means in the highly competitive space, and about the flexibility of FDA guidance for weight-management products
You may also be interested in...
Two potentially important mid-stage programs in the obesity research space are off the partnering table with the announcement Nov. 1 that Takeda and Amylin have teamed up to develop and commercialize several obesity candidates, including pramlintide/metreleptin and davalintide
Obesity research space is red hot, and now one of the key players has signed a big pharma partner; under the deal Amylin will get $75 million upfront.
Results raise doubts about prospects for regulatory approval and competitive positioning.